Characteristics of the studies.

<p>Characteristics of the studies.</p

Annual event rate on each randomized regimen.

<p>Annual event rate on each randomized regimen.</p

Estimated annual event rates for myocardial infarction and stent thrombosis in the short-DAPT group during aspirin mono-therapy.

<p>The landmark data was not available for myocardial infarction in the RESET and EXCELLENT trials. NA = not available.</p

Forest plot with OR of prolonged-DAPT relative to short-DAPT for each clinical outcome for the DAPT trial and the pooled population excluding the DAPT trial.

<p>ORs are shown on a logarithmic scale. CI = confidence interval, DAPT = dual anti-platelet therapy, and OR = odds ratio.</p

Definitions of the study endpoint.

<p>Definitions of the study endpoint.</p

Fig 2 -

Crude kaplan-meier curves for the cumulative incidence of (A) all-cause death/MI/stroke, (B) all-cause death, (C) any coronary revascularization, and (D) all-cause death/MI/stroke/any coronary revascularization. PCI = percutaneous coronary intervention; CABG = coronary artery bypass grafting; MI = myocardial infarction.</p

Baseline characteristics, medications, angiographic and procedural characteristics during the index hospitalization in the propensity score-matched cohort.

(DOCX)</p

List of clinical research coordinators.

(DOCX)</p

Subgroup analyses for the primary outcome measure (death/MI/stroke).

Subgroup analyses for the primary outcome measure (death/MI/stroke).</p

Kaplan-Meier event curves for clinical outcomes in patients with two-vessel or three-vessel disease including proximal LAD.

(TIF)</p